Three cardiometabolic-related news items have been observed: Inventiva announced changes to the clinical development of lanifibranor, including a new Ph3 trial in NASH and compensated cirrhosis (view press release); Galectin announced enrollment completion for its Ph2b/3 NAVIGATE study evaluating belapectin in patients with liver cirrhosis caused by NASH (view press release; CT.gov record); and Fujifilm Cellular Dynamics announced an iPSC-derived cell therapy license agreement with Novo Nordisk (view press release). Below, FENIX provides highlights and insights for the respective news items, including readthrough from Inventiva’s new NASH clinical development strategy.